ANIK Valuation

Anika Therapeutics Inc

Add to Watchlist

Advanced Chart

8.220

-0.03(-0.364%)1D

Overview
Forecast
Valuation
Earnings

ANIK Relative Valuation

ANIK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANIK is overvalued; if below, it's undervalued.

Historical Valuation

Anika Therapeutics Inc (ANIK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.06 is considered Undervalued compared with the five-year average of 201.80. The fair price of Anika Therapeutics Inc (ANIK) is between 23.31 to 33.66 according to relative valuation methord. Compared to the current price of 8.22 USD , Anika Therapeutics Inc is Undervalued By 64.74%.

Relative Value

Fair Zone

23.31-33.66

Current Price：8.22

64.74%

Undervalued

206.25

Trailing

Forward

24.83

EV/EBITDA

Anika Therapeutics Inc. (ANIK) has a current EV/EBITDA of 24.83. The 5-year average EV/EBITDA is -61.58. The thresholds are as follows: Strongly Undervalued below -907.27, Undervalued between -907.27 and -484.42, Fairly Valued between 361.27 and -484.42, Overvalued between 361.27 and 784.11, and Strongly Overvalued above 784.11. The current Forward EV/EBITDA of 24.83 falls within the Historic Trend Line -Fairly Valued range.

-6.81

EV/EBIT

Anika Therapeutics Inc. (ANIK) has a current EV/EBIT of -6.81. The 5-year average EV/EBIT is -254.24. The thresholds are as follows: Strongly Undervalued below -1923.63, Undervalued between -1923.63 and -1088.93, Fairly Valued between 580.45 and -1088.93, Overvalued between 580.45 and 1415.15, and Strongly Overvalued above 1415.15. The current Forward EV/EBIT of -6.81 falls within the Historic Trend Line -Fairly Valued range.

1.06

Anika Therapeutics Inc. (ANIK) has a current PS of 1.06. The 5-year average PS is 2.64. The thresholds are as follows: Strongly Undervalued below 0.98, Undervalued between 0.98 and 1.81, Fairly Valued between 3.47 and 1.81, Overvalued between 3.47 and 4.31, and Strongly Overvalued above 4.31. The current Forward PS of 1.06 falls within the Undervalued range.

15.13

P/OCF

Anika Therapeutics Inc. (ANIK) has a current P/OCF of 15.13. The 5-year average P/OCF is 152.54. The thresholds are as follows: Strongly Undervalued below -803.46, Undervalued between -803.46 and -325.46, Fairly Valued between 630.55 and -325.46, Overvalued between 630.55 and 1108.55, and Strongly Overvalued above 1108.55. The current Forward P/OCF of 15.13 falls within the Historic Trend Line -Fairly Valued range.

-450.90

P/FCF

Anika Therapeutics Inc. (ANIK) has a current P/FCF of -450.90. The 5-year average P/FCF is -2.46. The thresholds are as follows: Strongly Undervalued below -553.07, Undervalued between -553.07 and -277.76, Fairly Valued between 272.85 and -277.76, Overvalued between 272.85 and 548.16, and Strongly Overvalued above 548.16. The current Forward P/FCF of -450.90 falls within the Undervalued range.

Anika Therapeutics Inc (ANIK) has a current Price-to-Book (P/B) ratio of 0.81. Compared to its 3-year average P/B ratio of 1.44 , the current P/B ratio is approximately -44.09% higher. Relative to its 5-year average P/B ratio of 1.58, the current P/B ratio is about -49.18% higher. Anika Therapeutics Inc (ANIK) has a Forward Free Cash Flow (FCF) yield of approximately -0.44%. Compared to its 3-year average FCF yield of -1.31%, the current FCF yield is approximately -66.01% lower. Relative to its 5-year average FCF yield of -0.07% , the current FCF yield is about 504.10% lower.

0.81

P/B

Median3y

1.44

Median5y

1.58

-0.44

FCF Yield

Median3y

-1.31

Median5y

-0.07

Competitors Valuation Multiple

The average P/S ratio for ANIK's competitors is 6.74, providing a benchmark for relative valuation. Anika Therapeutics Inc Corp (ANIK) exhibits a P/S ratio of 1.06, which is -84.32% above the industry average. Given its robust revenue growth of -8.15%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ANIK.O

Anika Therapeutics Inc

BioSig Technologies Inc

Anteris Technologies Global Corp

23.94

130.18M

LUCD.O

Lucid Diagnostics Inc

13.05

-17.28%

106.12M

Performance Decomposition

Market capitalization of ANIK decreased by 67.90% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -8.27 to -16.47.

The secondary factor is the Revenue Growth, contributed -8.15%to the performance.

Overall, the performance of ANIK in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-8.15%

30.72M → 28.22M

Revenue Growth

99.15%

-8.27 → -16.47

Margin Expansion

-158.90%

15.62 → -9.20

P/E Change

-67.90%